Notícias e Atividades da MPM BioImpact

Veja o organograma con seus 29 executivos principais

Biografias mais buscadas da MPM BioImpact

• Christiana Bardon, Managing Partner
• Ansbert Gadicke, Managing Partner
• Matthew Roden, Entrepreneur Partner

Recentes movimentos de executivos em MPM BioImpact

• Brian Shuster, ingressou na Companhia como Entrepreneur Partner  (Notícia publicada em 9 de janeiro de 2025).

Criar um alerta
para seguir os movimentos de executivos da MPM BioImpact.

MPM BioImpact possui 1.570 concorrentes concorrentes BlackRock (Estados Unidos), Vanguard (Estados Unidos) e Blackstone Group (Estados Unidos).

Popular M&A news in Fundo

• Seven2 has announced the acquisition of HRK Lunis  (publicado em 3 de abril de 2025).
• Fluent adquiriu RIV Capital (publicado em 20 de dezembro de 2024).
• RIV Capital and Fluent have announced they will merge  (publicado em 14 de outubro de 2024)..

Outros contatos sugeridos na indústria do Fundo

• Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer da Valor Equity Partners
• Salim Ramji - Chief Executive Officer and Director da Vanguard
• Hemant Taneja - Chief Executive Officer and Managing Director da General Catalyst Partners

Saiba mais sobre a indústria do Fundo

Últimos comunicados de imprensa de MPM BioImpact

• DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved | DBV Technologies
• Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy | Cullin
• Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
• MPM BioImpact Announces Promotion of Rami Rahal, Ph.D., to Partner
• MPM BioImpact Appoints Brian Shuster, Experienced in Healthcare Corporate Development, as Entrepreneur Partner
• Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation | Syndax Pharmaceuticals, Inc.
• MPM BioImpact Appoints Michael Ehlers, M.D., Ph.D., Experienced R&D Leader and Accomplished Biotechnology Executive, as Entrepreneur Partner
• AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED SERIES B FINANCING TO FURTHER ADVANCE ITS PROPRIETARY RADIOPHARMACEUTICAL PIPELINE - Aktis
• AKTIS ONCOLOGY APPOINTS AKOS CZIBERE, MD, PhD, CHIEF MEDICAL OFFICER - Aktis
• NextPoint Therapeutics Chief Executive Officer Ivan Cheung Named to the 2024 TIME100 Health List
• View more press releases Close

Redes sociais sobre MPM BioImpact

• MPM BioImpact na Wikipedia, Google News e Yahoo Finance
• MPM BioImpact na LinkedIn, Twitter e YouTube